NAD (Nicotinamide Adenine Dinucleotide) history of use

     Has been used since the late 1960s in intravenous form to significantly lessen withdrawal from a variety of drugs and alcohol
     Mechanism not clear
     Limitation is that recovery tends not to be complete with IV NAD alone
     With addition of specified amino acids complex, recovery is found to be significantly more profound, complete and lasting

    NAD functions

     Primarily a universal cellular electron transporter Several recognized non-redox roles:

     Important in cell nuclear DNA repair and telomere maintenanceˡ
    Extracellular signaling molecule:
     From neurons in blood vessels, urinary bladder², large intestine; and transcription regulation and aging via sirtuinsᶾ

    Released from neurosecretory cells and brain synaptosomes⁴

    Future of IV NAD

     Safety – Inherently safe at doses of 2 gms/day or less  Generally give 800 to 1800 mg per day, over 3-8
     Treatment for 7-16 days, depending on drug history  Able to address benzodiazepine dependence
     Clearly the best current solution to the expanding problems of drug abuse (particularly heroin), prescription drug abuse, and post-acute withdrawal syndrome (PAWS)



     1. Bürkle A (2005). “Poly(ADP-ribose). The most elaborate metabolite of NAD+.” FEBS J. 272 (18): 4576–89.
     2. Smyth LM, Bobalova J, Mendoza MG, Lew C, Mutafova- Yambolieva VN (2004). “Release of beta-nicotinamide adenine dinucleotide upon stimulation of postganglionic nerve terminals in blood vessels and urinary bladder.” J Biol Chem. 279 (47): 48893–903
     3. Blander G, Guarente L (2004). “The Sir2 family of protein deacetylases.” Annu. Rev. Biochem. 73: 417–35
     4. Billington RA, Bruzzone S, De Flora A, Genazzani AA, Koch-Nolte F, Ziegler M, Zocchi E (2006). “Emerging functions of extracellular pyridine nucleotides.” Mol Med. 12 (11–12): 324–7.

     5. Broom SL, Owen S, Norris P, Mestayer R, Grace C, Shen G, Hitt W (2008). “Amino acid-based nutritional supplementation facilitates abrupt cessation (“stopping cold turkey”) of substance use by addiction patients: Reduction of withdrawal symptoms with minimal abuse potential.” Presentation, Soc. for Neuroscience annual meeting, 19 Nov. 2008.
     6. Humiston J (2014). “Treatment of Drug and Alcohol Dependence and Chronic Pain with Intravenous Amino Acids.” Meeting of the Int’l College of Integrative Medicine, Dearborn, Michigan, 25 Sept. 2014.

    error: Content is protected !!